Divi's Laboratories · NSE: DIVISLAB · BSE: 532488
Q1 FY22 results · Apr–Jun 2021
Divi's Laboratories reported revenue from operations of ₹1,960.64 crore (up 13.3% from Q1 FY21) and net profit of ₹557.11 crore (up 13.2% from Q1 FY21) for Q1 FY22 (Apr–Jun 2021), on a consolidated basis.
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,960.64 | 1,730.47 | +13.3% | 1,788.19 | +9.6% |
| Other income | 35.97 | 17.33 | +107.6% | 23.52 | +52.9% |
| Total income | 1,996.61 | 1,747.80 | +14.2% | 1,811.71 | +10.2% |
| Profit before tax | 814.48 | 660.98 | +23.2% | 669.49 | +21.7% |
| Net profit for the period | 557.11 | 492.06 | +13.2% | 502.02 | +11.0% |
| Attributable to shareholders of the company | 558.88 | 492.06 | +13.6% | 502.02 | +11.3% |
| EPS, basic (₹) | 20.99 | 18.54 | +13.2% | 18.91 | +11.0% |
| Net margin (%) | 28.4 | 28.4 | 28.1 |
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,950.16 | 1,709.96 | +14.0% | 1,718.39 | +13.5% |
| Other income | 35.55 | 17.87 | +98.9% | 22.85 | +55.6% |
| Total income | 1,985.71 | 1,727.83 | +14.9% | 1,741.24 | +14.0% |
| Profit before tax | 813.77 | 660.70 | +23.2% | 652.18 | +24.8% |
| Net profit for the period | 551.97 | 492.25 | +12.1% | 487.93 | +13.1% |
| EPS, basic (₹) | 20.79 | 18.54 | +12.1% | 18.38 | +13.1% |
| Net margin (%) | 28.3 | 28.8 | 28.4 |
Consolidated
- Filed with BSE
- 07 Aug 2021, 17:08 IST
- Board meeting
- 07 Aug 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 07 Aug 2021, 17:08 IST
- Board meeting
- 07 Aug 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE